Onkologie. 2014:8(5):228-230
Hormonal therapy for prostate cancer
- Onkologicko-chirurgické oddělení, FN u sv. Anny, Brno
Prostate cancer is initially a hormone-sensitive disease. The mainstay of treatment is androgen deprivation therapy (ADT) in combination
with radiotherapy in localized disease with no evidence of distant metastases in high-risk patients. Pharmacological or surgical castration
in monotherapy is also used in the first-line treatment of metastatic disease. Hormonal therapy has been shown to have an effect
on survival in castration-resistant disease. The results of studies with abiraterone and enzalutamide have shown that antiandrogens
can be expected to be beneficial in metastatic castration-resistant prostate cancer (mCRPC) even after pretreatment with docetaxel.
Keywords: androgen deprivation therapy, abiraterone, enzalutamide
Published: October 16, 2014 Show citation
References
- Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from Prostate Cancer Outcomes Study. J Clin Oncol 2001; 19: 3750-3757.
Go to original source... 
Go to PubMed... - Prostate Cancer Trialist´s Collaborative Group. Maximum androgen blocade in advanced prostate cancer; an overwiew of the randomized trials. Lancet 2000; 339: 1491-1498. Go to original source...
- Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001; 58(Suppl 1): 5-9. Go to original source... Go to PubMed...
- Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118. Go to original source... Go to PubMed...
- Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer. (an EORTC study): a phase III randomized trial. Lancet 2002; 360: 103-106. Go to original source... Go to PubMed...
- Bolla M, de Reijke, Van Tienhoven C, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009; 360: 2516-2527. Go to original source... Go to PubMed...
- Ryan CHJ, Londhe A, Molina A, Smith MR, De Bono JS, Mulders R, et al. Relationship of baseline PSA and degree of PSA decline to radiographic progression-free survival (rPFS) in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302. J Clin Oncol 31, 2013 (suppl; abstr 5010). Go to original source...
- de Bonno JS, Logothetis ChJ, et al. Abiraterone and Oncreased Survival in Metastatic Prostate Cancer. N Engl J Med. 2011; 364: 1995-2005. Go to original source... Go to PubMed...
- Saad F, Fizazi K, Smith MR, Griffin TW, et al. Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P). J Clin Oncol 31, 2013(suppl; abstr 5037). Go to original source...
- Tran C, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790. Go to original source... Go to PubMed...
- Hu R, et al. Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer. Expert Rev Endocrinol Metab 2010; 5: 753-764. Go to original source... Go to PubMed...
- Scher HI, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Eng J Med 2012; 367: 1187-1197. Go to original source... Go to PubMed...